Semaglutide found to cut major adverse cardiovascular events in people with overweight, obesity
Semaglutide reduces cardiovascular events, regardless of baseline glycated hemoglobin (HbA1c), among people with overweight or obesity and established atherosclerotic cardiovascular disease, according to a study published ...
Jul 9, 2024
0
0
